A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Psoriasis is a chronic inflammatory hyperproliferative disease of the skin affecting
approximately 2% of the world's population.This phase IV study is planned to monitor
performance of Tinefcon in patients suffering from psoriasis under conditions of actual use
and fulfill requirements to monitor all adverse drug reactions (ADRs) in psoriasis patients
treated with Tinefcon. This study will add to literature on the risks and benefits of
Tinefcon the novel oral TNF-alpha release inhibitor.